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Background: Mitochondrial reactive oxygen species (ROS) levels and nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB) activity are increased in a lamb
model of persistent pulmonary hypertension of the newborn (PPHN). These events can
trigger hypoxia inducible factor (HIF) signaling in response to hypoxia, which has been
shown to contribute to pulmonary vascular remodeling in rodent models of pulmonary
hypertension. However, the role of HIF signaling in chronic intrauterine pulmonary
hypertension is not well understood.
Aim: To determine if HIF signaling is increased in the lambmodel of PPHN, and to identify
the underlying mechanisms.
Results: PPHNwas induced in lambs by antenatal ligation of the ductus arteriosus at 128
days gestation. After 9 days, lungs and pulmonary artery smooth muscle cells (PASMC)
were isolated from control and PPHN lambs. HIF-1α expression was increased in PPHN
lungs and HIF activity was increased in PPHN PASMC relative to controls. Hypoxia
increased HIF activity to a greater degree in PPHN vs. control PASMC. Control PASMC
were exposed to cyclic stretch at 1Hz and 15% elongation for 24 h, as an in vitro model
of vascular stress. Stretch increased HIF activity, which was attenuated by inhibition of
mitochondrial complex III and NFκB.
Conclusion: Increased HIF signaling in PPHN is triggered by stretch, via mechanisms
involving mitochondrial ROS and NFκB. Hypoxia substantially amplifies HIF activity in
PPHN vascular cells. Targeting these signaling molecules may attenuate and reverse
pulmonary vascular remodeling associated with PPHN.
Keywords: pulmonary hypertension, hypoxia, vascular stress, reactive oxygen species, HIF-1α
Introduction
At birth, the lung replaces the placenta as the organ of gas exchange. When the newborn
takes its first breath, the sudden increase in lung oxygenation reverses hypoxic pulmonary
vasoconstriction, resulting in an 8–10 fold increase in pulmonary blood flow (Dawes et al., 1953).
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Complex physiological and biochemical processes facilitate
the fetal to newborn transition, and abnormal lung develop-
ment and/or vascular dysfunction may disrupt these events.
Failure to adapt to postnatal life results in persistent pul-
monary hypertension of the newborn (PPHN), character-
ized by elevated pulmonary vascular resistance, right-to-left
extrapulmonary shunting of deoxygenated blood and severe
hypoxemia (Steinhorn, 2010). Some degree of PPHN compli-
cates the course of approximately 10% of term and preterm
infants with respiratory failure, and increases the risk of
death, pulmonary morbidity, and neurodevelopmental impair-
ment (Konduri et al., 2004). PPHN is associated with a severely
remodeled pulmonary vasculature, including increased thick-
ness of the smooth muscle layer within small pulmonary arter-
ies and abnormal extension of this muscle to non-muscular
arteries (Haworth and Reid, 1976). The extent of pulmonary
vascular remodeling correlates with the severity of the disease,
although the in utero mechanisms that disrupt normal develop-
ment and adaptation of the pulmonary circulation remain poorly
understood.
A better understanding of the underlying mechanisms that
trigger pulmonary vascular remodeling and vasoconstriction is
warranted to develop new therapies and preventative strategies
for PPHN. In fetal lambs, constriction of the ductus arteriosus
produces fetal and neonatal pulmonary hypertension (Abman
et al., 1989;Morin, 1989;Wild et al., 1989; Black et al., 1998). After
delivery, these lambs have persistent hypoxemia and elevation
of PVR, providing an important experimental model of human
infants with PPHN. This model of PPHN is associated with strik-
ing pulmonary vascular remodeling along with elevated levels
of reactive oxygen species (ROS) in the lungs and pulmonary
arteries (Brennan et al., 2003; Wedgwood et al., 2005), and ROS
have been implicated in impaired pulmonary vasodilation and
increased smooth muscle proliferation.
After birth, chronic hypoxia also induces pulmonary vascular
abnormalities characteristic of PPHN in several animal mod-
els including newborn piglets (Allen and Haworth, 1986; Tul-
loh et al., 1997) and newborn mice (Ambalavanan et al., 2005).
Hypoxia inducible factors (HIF) are highly conserved transcrip-
tion factors that are expressed in multiple cell types, and control
the oxygen-dependent expression of numerous genes (Shimoda
and Laurie, 1985). Because heterozygous mice lacking one HIF-
1α allele display attenuated hypoxia-induced pulmonary vascular
remodeling and pulmonary hypertension (Yu et al., 1999), HIFs
are believed to play an important role in pulmonary vascular
signaling.
In vitro studies have identified ROS as intermediates in
hypoxic stabilization of HIF-1α protein (Guzy et al., 2005), sug-
gesting that elevated ROS levels and subsequent HIF-induced
transcription may contribute to vasoconstriction and vascular
remodeling in PPHN. However, the involvement of HIFs in the
development of pulmonary hypertension and smooth muscle
proliferation in PPHN lambs is currently unknown. The pur-
pose of this study is to quantify HIF-1α expression in lungs
and pulmonary artery smooth muscle cells (PASMC) isolated
from PPHN lambs relative to controls, and to use in vitro tech-
niques to investigate the mechanisms involved. Identification
of a major regulator of abnormal gene expression may reveal
novel therapeutic targets for the prevention and treatment
of PPHN.
Materials and Methods
Animals
This protocol was approved by the Laboratory Animal Care
committee at University at Buffalo and University of Califor-
nia, Davis. Time-dated pregnant ewes were obtained from Swartz
family farm in Attica, NY. Fetal lambs underwent antenatal
ligation of the ductus arteriosus at 128 days gestation (term
143–145 days) to induce pulmonary hypertension as previously
described (Morin, 1989; Zayek et al., 1993). Lambs were deliv-
ered 9 days later and sacrificed with an overdose of thiopental
sodium and exsanguination before their first breath. Fifth genera-
tion pulmonary arteries and lung tissue were collected for further
analysis.
Western Blot Analysis
Lung tissue was homogenized and total protein collected using
the PARIS kit (Ambion, Austin, TX) as previously described
(Farrow et al., 2008a). Protein lysates from PASMC were pre-
pared using 1X Mg-lysis buffer (Upstate, Charlottesville, VA)
supplemented with a protease inhibitor cocktail (Sigma). Pro-
tein concentration was measured using the Bradford method
(Bradford, 1976). Total protein (40µg) was separated on a 4–
20% SDS-polyacrylamide gel (Biorad, Hercules, CA) and then
transferred to a nitrocellulose membrane (Amersham, Arling-
ton Heights, IL). Western blot was then performed as previ-
ously described (Farrow et al., 2008a,b). Briefly, membranes
were blocked at room temperature with 5% non-fat dry milk
in Tris-buffered saline containing 0.1% Tween 20 (1X TBST)
and were then incubated overnight at 4◦C with a mouse anti-
HIF-1α antibody (Novus Biologicals, Littleton, CO) in 5% milk
+ 1X TBST at a 1:1000 dilution. The membranes were washed
and incubated with an anti-mouse secondary antibody conju-
gated to horseradish peroxidase (Pierce, Rockford, IL) diluted
1:1000 in 5% milk + 1X TBST. Membranes were washed
and exposed via chemiluminescence (Pierce). Bands were ana-
lyzed using a Digital Science Image Station (Kodak, Rochester,
NY). Expression within each Western blot was normalized
to β-actin.
Immunocytochemistry
Cells were seeded onto microscope slides and fixed with 4%
paraformaldehyde. Slides were blocked with 5% BSA (Sigma) +
1X TBST at room temperature for 1 h and then probed overnight
at 4◦C with anti-HIF-1α antibody (1:100 dilution). Slides were
washed and probed with a Rhodamine Red Goat anti-mouse sec-
ondary antibody (Molecular Probes/Invitrogen) at a 1:200 dilu-
tion in 5% BSA. Localization and expression was visualized with
a Nikon Eclipse TE-300 fluorescent microscope with excitation
at 518 nm and emission at 605 nm. Fluorescent images were cap-
tured using a CoolSnap digital camera with Metamorph imaging
software (Molecular Devices, Sunnyvale, CA).
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Cell Culture
Primary cultures of pulmonary arterial smooth muscle cells
(PASMC) from control and PPHN fetal lambs were isolated by
the explant technique and maintained in culture as described
previously (Wedgwood et al., 2001). Briefly, a segment of the
main pulmonary artery from 136-day-old fetal lambs was excised
and placed in a sterile 100mm dish containing Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 1 g/l glucose
(Mediatech, Herndon, VA). The segment was stripped of adven-
titia with a sterile forceps. The main pulmonary artery seg-
ment was then cut longitudinally to open the vessel, and the
endothelial layer was removed by gentle rubbing with a cell
scraper. The vessel was then cut into 2-mm segments, inverted,
and placed on a collagen-coated 35-mm tissue culture dish.
A drop of DMEM containing 10% fetal bovine serum (FBS;
HyClone, Logan, UT), antibiotics (MediaTech), and antimy-
cotics (Mediatech) was then added, and the cells were grown
overnight at 37◦C in a humidified atmosphere with 5% CO2–
95% air. The next day, an additional 2ml of complete medium
were added. The growth medium was subsequently changed
every 2 days. When SMC islands could be observed under
the microscope, the tissue segment was removed and the indi-
vidual cell islands were subcloned. Identity was confirmed as
PASMCs by immunostaining (>99% positive) with antibod-
ies against α-smooth muscle actin, calponin and caldesmon.
This was taken as evidence that cultures were not contami-
nated with fibroblasts or with endothelial cells. All cultures for
subsequent experiments were maintained in DMEM supple-
mented with 10% fetal calf serum (Hyclone), antibiotics (Medi-
aTech), and antimycotics (MediaTech) at 37◦C in a humidified
atmosphere with 5% CO2–95% air. Cells were used between
passages 2–5.
Plasmid DNA Transfection and Luciferase Assays
HIF promoter activity was determined using the pGL4.42
[luc2P/HRE/Hygro] plasmid containing 4 consensus HRE
sequences fused to a luciferase reporter (HRE-luc) and NFκB
promoter activity was determined using the pGL4.32 [luc2P/NF-
κB-RE/Hygro] plasmid containing five consensus NFκB response
elements fused to a luciferase reporter (NFκB-luc) (both
Promega, Madison, WI). PASMC were co-transfected with 4µg
of plasmid DNA and 0.1µg pRL-CMV Vector (Promega) on
a 10 cm2 tissue culture plate at 60% confluence, using Lipofec-
tamine (Gibco BRL) according to the manufacturer’s instruc-
tions. After 24 h cells were split onto 6-well plates (hypoxia)
or BioFlex plates (cyclic stretch) and allowed to adhere. Cells
were synchronized in serum-free DMEM for 24 h, returned to
DMEM containing 10% serum and exposed to hypoxia or to
cyclic stretch as described below. Luciferase activity in pro-
tein extracts was determined using the Dual-Luciferase Reporter
Assay System (Promega) and a Femtomaster FB12 luminome-
ter (Zylux). Activity was normalized to the internal renilla
luciferase control to correct for differences in transfection
efficiencies. Where appropriate, cells were treated with 1µM
myxothiazol or 10µMHelenalin (Calbiochem) prior to luciferase
assays.
Hypoxia
Cells were transfected with the HRE-luc promoter construct plas-
mid as described above. PASMCs were returned to DMEM con-
taining 10% serum and maintained in an incubator with 21%
O2–5% CO2 or exposed to 5% O2–5% CO2in a Coy chamber
(CoyLabs, Grass Lake, MI) for 24 h.
Cyclic Stretch
Cells were transfected with HRE-luc and NFκB-luc promoter
construct plasmids as described above, seeded onto six-well
BioFlex plates coated with collagen type IV (FlexCell) and sub-
jected to biaxial cyclic stretch using the FlexCell 3000 Strain Unit.
Plates were placed on a loading station and stretched by applying
an oscillatory vacuum to the underside of the membranes. Cells
were stretched at a frequency of 1Hz with 15% amplitude for 24 h
in accordance with a previous study (Quinn et al., 2002).
Statistical Analysis
Means ± SEM were calculated from individual experiments
and expressed as fold change relative to the same internal con-
trol: control lungs (HIF-1α expression), control PASMC in nor-
moxia (hypoxia experiments) or to static control cells treated
with vehicle where appropriate (stretch experiments). Results
were analyzed by two-sided unpaired t-test or by ANOVA with
Newman-Keuls post-hoc testing using Prism software (GraphPad
Software Inc., San Diego, CA). Statistical significance was set at
p < 0.05.
Results
Total lung HIF-1α protein levels were increased in lung sam-
ples from PPHN lambs relative to controls as detected by
Western blotting (Figure 1A). When normalized to β-actin, nor-
moxic expression of HIF-1α was 1.6-fold higher in PPHN lungs
(Figure 1B, ∗p < 0.05).
Nuclear HIF-1α protein levels were higher in PPHN vs. con-
trol PASMC cultured in normoxia as detected by immunocy-
tochemistry (Figure 2A). To quantify cellular HIF activity we
utilized a plasmid containing four consensus hypoxia response
elements (HRE), a DNA binding sequence for HIFs in target
gene promoters, fused to a luciferase reporter (HRE-luc). Nor-
moxic HIF activity was 3.6-fold higher in PPHN PASMC rela-
tive to controls (Figure 2B, ∗p < 0.05). Hypoxia dramatically
increased HIF activity to 6.9-fold and 23.8-fold in control and
PPHN PASMC respectively relative to normoxic control cells
(Figure 2B, ∗p < 0.05). Under hypoxic conditions, HIF activ-
ity was 3.4-fold higher in PPHN PASMC relative to control cells
and 6.6-fold higher in PPHN PASMC relative to normoxic PPHN
PASMC (Figure 2B, †p < 0.05).
Cyclic stretch increased HIF activity in control PASMC by
1.8-fold relative to static cells (Figure 3, ∗p < 0.05). Inhibition
of mitochondrial complex III with myxothiazol decreased basal
HIF activity in static cells (Figure 3, ∗p < 0.05) Stretch-induced
HIF activity was attenuated by the mitochondrial complex III
inhibitor myxothiazol (Figure 3, †p < 0.05).
Cyclic stretch increased NFκB promoter activity in control
PASMC by 1.5-fold relative to static cells (Figure 4A, p < 0.05).
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FIGURE 1 | HIF-1α expression is increased in PPHN lungs (A)
Representative blots for HIF-1α from control and PPHN lungs. Lysates
from two different animals in each group are depicted. (B) Expression levels
were normalized to β-actin levels and expressed as fold change relative to
controls. ∗p < 0.05. N = 4 animals.
Stretch-induced HIF activity in control PASMC was attenuated
by the NFκB inhibitor helenalin (Figure 4B, p < 0.05).
Discussion
Newborns with PPHN that die shortly after birth display extreme
hypertensive structural remodeling (Geggel and Reid, 1984), sug-
gesting that the most severe cases of disease stem from chronic
intrauterine stress. Determining the intrauterine events that
alter pulmonary vascular reactivity and structure is essential to
improve early detection and treatment. In this study we iden-
tified elevated HIF-1α expression in the lungs (Figure 1), and
elevated HIF activity in PASMC (Figure 2), as potential regu-
lators of abnormal gene expression in PPHN lambs. Antenatal
surgical closure of the ductus arteriosus results in a sustained ele-
vation of pulmonary arterial pressure in PPHN lambs (Storme
et al., 1999). Cyclic stretch mimics increased pulmonary artery
pressure, and in the current study we found that cyclic stretch
increased HIF activity in PASMC isolated from control lambs
via mechanisms involving mitochondrial complex III (Figure 3)
and NFκB (Figure 4). Targeting the signaling pathways that stim-
ulate HIF activity and the genes that are upregulated by HIFs
(Figure 5) may represent a novel strategy for the treatment of
PPHN (Table 1).
Elevated HIF expression and activity in lungs and PASMC
may contribute to abnormal gene expression that has been
demonstrated previously in PPHN lambs. HIFs are heterodimers
consisting of oxygen-sensitive α-subunits (HIF-1α, HIF-2α) and
constitutively expressed β subunits. Hypoxia stabilizes the α
FIGURE 2 | HIF-1α nuclear expression and activity is increased in
PPHN PASMC (A) Representative immunocytochemistry images from
control and PPHN PASMC depicting nuclear localization of HIF-1α
and the corresponding light phase image. (B) Control and PPHN
PASMC were transfected with a plasmid containing four consensus HRE
sequences upstream of a luciferase reporter (HRE-luc). Cells were
maintained in normoxia or exposed to 1.5% O2 for 24 h before assay.
Relative light units were determined in a luminometer, normalized to an
internal renilla luciferase control plasmid and expressed as fold change
relative to control cell lysates. ∗p < 0.05 vs. control normoxia; †p < 0.05 vs.
control hypoxia and PPHN normoxia. N = 4.
subunit leading to nuclear accumulation and activation of mul-
tiple target genes (Shimoda and Laurie, 1985). The fetus is
programmed to develop under hypoxic conditions, and HIF
expression is essential to normal fetal lung development. Basal
HIF expression has been reported to be higher in the fetal
relative to the adult lung (Resnik et al., 2007), and deletion
of the HIF gene is lethal during fetal life. Tamoxifen-induced
silencing of smooth muscle HIF-1α expression attenuates pul-
monary vascular remodeling and pulmonary hypertension in
chronically hypoxic mice (Ball et al., 2014), suggesting a cen-
tral role for HIF-1α in the pulmonary vascular response to
hypoxia. Interestingly, increased lung HIF-1α expression is also
evident in a lamb model of pulmonary hypertension secondary
to congenital heart disease and vascular stress from increased
pulmonary blood flow (Diebold et al., 2010a). Together these
data suggest that elevated HIF signaling may contribute to
pulmonary vascular remodeling and pulmonary hypertension
in PPHN.
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FIGURE 3 | Inhibition of mitochondrial complex III attenuates
stretch-induced HIF activity. Control PASMC were transfected with the
HRE-luc plasmid, treated with vehicle (Veh) or with 1µM myxothiazol (myx) to
inhibit complex III, and subjected to 24 h cyclic stretch at 1Hz and 15%
elongation. Relative light units were determined in a luminometer, normalized
to an internal renilla luciferase control plasmid and expressed as fold change
relative to control cell lysates. ∗p < 0.05 vs. static vehicle; †p < 0.05 vs.
stretch vehicle. N ≥ 4.
We found that hypoxia increased HIF activity in PASMC
by 6.9-fold in control PASMC and 6.6-fold in PPHN PASMC
(Figure 2B). Since normoxic HIF activity is almost 4-fold higher
in PPHN PASMC (Figure 2B), the hypoxic intrauterine environ-
ment of the developing fetus may exacerbate abnormal HIF sig-
naling during disease progression. Previous reports suggest that
smooth muscle HIF-1αmay contribute to the sustained vasocon-
strictor response to hypoxia (Ball et al., 2014), and our findings
may partly explain why PPHN lambs have greatly enhanced vaso-
constrictor responses in response to hypoxia (Lakshminrusimha
et al., 2009). However, the mechanisms that elevate HIF activity
under normoxic conditions are poorly understood.
In vitro models can be useful to investigate novel signaling
pathways. In PPHN lambs, occlusion of the ductus arteriosus
generates a myogenic response where stretch-induced vasocon-
striction opposes the increase in pulmonary blood flow, resulting
in a sustained elevation of pulmonary arterial pressure (Storme
et al., 1999). In the current study we exposed control PASMC
to cyclic stretch to mimic increased pulmonary artery pressure,
and demonstrated that 24 h stretch increased HIF activity relative
to static controls (Figure 3). Stretch also increases expression of
HIF-1α in rat aortic SMC (Chang et al., 2003) in agreement with
our results. We also found that stretch-induced HIF activity was
attenuated by the mitochondrial complex III inhibitor myxoth-
iazol (Figure 3). Hypoxic stabilization of HIF-1α involves the
release of ROS from mitochondrial complex III into the cytosol
(Guzy et al., 2005). Under normoxic conditions, PASMC isolated
from PPHN lambs have increased levels of mitochondrial (Far-
row et al., 2010) and cytosolic (Wedgwood et al., 2011) ROS
relative to controls. We recently reported that exposure of con-
trol PASMC to cyclic stretch increases cytosolic ROS levels (Shah
et al., 2013), while mitochondrial inhibitors attenuate stretch-
induced ROS in pulmonary artery endothelial cells (Ali et al.,
2006). Together these data suggest that elevated mitochondrial
FIGURE 4 | Stretch increases NFκB activity and NFκB inhibition
attenuates stretch-induced HIF activity. (A) Control PASMC were
transfected with a plasmid containing five consensus NFκB promoter elements
fused to luciferase reporter (NFκB-luc) and subjected to 24 h cyclic stretch at
1Hz and 15% elongation. (B) Control PASMC were transfected with the
HRE-luc plasmid, treated with vehicle (Veh) or with 10µM helenalin (hel) to
inhibit NFκB, and subjected to 24 h cyclic stretch at 1Hz and 15% elongation.
Relative light units were determined in a luminometer, normalized to an internal
renilla luciferase control plasmid and expressed relative to control cell lysates.
∗p < 0.05 vs. static (A) or static vehicle (B). †p < 0.05 vs. stretch vehicle.
N = 4.
and cytosolic ROS levels may contribute to increased HIF-1α
expression and activity in PPHN lungs and PASMC, and that
these abnormalities are sustained independent of hypoxia. Tar-
geting the pathways that stabilize HIFs under normoxic condi-
tions may attenuate abnormal gene expression characteristic of
PPHN, and provide therapeutic strategies that can reverse its
pulmonary vascular remodeling.
In the current study we extend our findings by showing
that stretch increased nuclear factor kappa B (NFκB) activity,
and that stretch-induced HIF activity was attenuated by the
NFκB inhibitor helenalin (Figure 4). NFκB upregulates HIF-1α
transcription in response to hypoxia in PASMC (Belaiba et al.,
2007), and we previously found elevated NFκB activity in PPHN
PASMC relative to controls (Wedgwood et al., 2013). From these
data we speculate that cyclic stretch triggers a release of ROS from
the mitochondria into the cytosol, thereby activating NFκB and
HIF and stimulating the expression of their target genes. We also
speculate that similar mechanisms are active in PPHN PASMC
(Figure 5).
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FIGURE 5 | Proposed HIF signaling pathway in PPHN. PPHN increases
mitochondrial ROS (Mito ROS) in smooth muscle cells, resulting in an increase
in cytosolic ROS. This increases NFκB and HIF activities, leading to increased
expression of target genes including NADPH oxidases (Nox). This stimulates a
feed forward mechanism that gives a sustained increase in Cyto ROS. PPHN
also increases HIF activity in endothelial cells, leading to an increase in
expression and release of ET-1. ET-1 activates ETA receptors (ETAR) on
adjacent smooth muscle cells, leading to vasoconstriction and increased
cytosolic ROS. Cytosolic ROS can stimulate vascular remodeling and
vasoconstriction as discussed in the text.
TABLE 1 | Proposed targets, roles in PPHN and potential pharmacologic
approaches.
Target Proposed role in PPHN Potential pharmacologic
approaches
Complex III Generates ROS in response to
stretch, hypoxia
Terpestacin, MitoQ
NFκB Amplifies gene expression in
response to ROS, stretch, hypoxia,
inflammation
Pyrrolidine
dithiocarbamate,
glucocorticoids
HIF Amplifies gene expression in
response to ROS, stretch, hypoxia
Glyceollins
Nox Generate sustained ROS in
response to stretch, hypoxia
Dysregulate enzymes important for
NO signaling
Pyrazolopyridine
derivatives (GKT137831),
triazolo pyrimidine
derivatives (VAS 2870)
ETAR Vasoconstriction and vascular
smooth muscle growth
Bosentan, Ambrisentan,
Macitentin
These pathways present a number of possible therapeu-
tic targets (Figure 5 and Table 1). Attenuating ROS pro-
duction from mitochondrial complex III and/or inhibiting
its target, NFκB, may prove effective in decreasing abnor-
mal HIF-mediated gene expression in PPHN. Mitochondrial
complex III inhibitors including terpestacin and MitoQ are
under investigation and have been used in mice to inhibit
tumor angiogenesis (Jung et al., 2010). In addition, pharma-
cological inhibition (Sawada et al., 2007) and nanoparticle
delivery of an NFκB decoy (Kimura et al., 2009) attenuate
pulmonary hypertension in rats, and our previous findings
suggest that the beneficial effects of glucocorticoids could
be partly mediated through NFκB inhibition (Perez et al.,
2014).
While direct inhibition of HIF could prevent or reverse the
vascular changes of pulmonary hypertension, currently only a
few of the putative small molecule inhibitors of HIF are progress-
ing through preclinical trials as anti-cancer agents (Galie et al.,
2004). Recently glyceollins, a group of novel phytoalexins iso-
lated from soybean, were found to decrease microvessel density
in solid tumor tissues via mechanisms involving decreased HIF-
1α protein synthesis (Lee et al., 2015). Furthermore, the effects of
HIF inhibition would need to be balanced with the requirement
of HIF for normal fetal lung development.
The proteins encoded by HIF-regulated genes may also rep-
resent attractive targets to attenuate the effects of abnormal HIF
signaling in PPHN. NADPH oxidases (Nox) are a major source of
vascular ROS and contribute to multiple cardiovascular diseases
(Lassegue and Griendling, 2009). mRNA and protein levels of
Nox2 (Wedgwood et al., 2012) andNox4 (Wedgwood et al., 2013)
are elevated in PPHN lungs and PASMC, and these Nox sub-
units are regulated by HIF-1α (Diebold et al., 2010b). This raises
the intriguing possibility of a feed forward mechanism in PPHN,
whereby Nox-derived ROS activate HIF, leading to increased Nox
expression and ROS generation. Another target for HIF is the
potent vasoconstrictor ET-1 (Galie et al., 2004), and ET-1 mRNA
levels are elevated in PPHN lambs (Black et al., 1998). ET-1 stim-
ulates proliferation via increased ROS (Wedgwood et al., 2001)
and increases HIF-1α expression (Pisarcik et al., 2013) in PASMC.
These data provide further evidence of a feed forward mecha-
nism in PPHN involving ROS, Nox, HIFs and ET-1. ET-1 stim-
ulates vasoconstriction mainly via ETA receptors, and selective
ETA receptor antagonists have proved to be successful in several
animal models of neonatal pulmonary hypertension (Kuo, 2001;
Perreault et al., 2001; Wagenaar et al., 2013).
In summary, our data suggest that cyclic stretch induces a
PPHN phenotype in control PASMC, including elevated ROS,
HIF and NFκB signaling, and may represent a useful in vitro
tool to study the abnormal in utero events that trigger PPHN.
However, there are several limitations to the study. Ideally, con-
trol PASMC would be exposed to stretch and hypoxia simultane-
ously to mimic the in utero PPHN environment. Also, co-culture
experiments would expose PASMC to vasoactive molecules
including ET-1 that are released by endothelial cells in response
to stretch. In this study we did not monitor HIF activity in vivo
and the lack of available small molecule inhibitors of HIFs means
that we are currently unable to determine the effects of attenuated
HIF signaling on pulmonary hypertension and vascular remod-
eling in PPHN lambs. However, this study has identified compo-
nents of the HIF signaling pathway that may contribute to the
pathogenesis of PPHN, and further studies are warranted in vivo
and in vitro to investigate further the mechanisms involved.
These studies will improve our current detection and treatment
strategies for babies with PPHN.
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